ASSOCIATION OF METABOLIC SYNDROMES AND BIOCHEMICAL MARKERS FOR THE PROGRESSION OF NONALCOHOLIC FATTY ACID DISEASE

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a cause and an outcome of metabolic syndrome (MetS). Globally, 6.3%-33% of the general population is affected, and metabolic co-morbidities increase the risk. This study aims to discover risk indicators, such as metabolic components and blood measurements, to predict sickness. For six months, 200 patients with NAFLD and 100 healthy controls were monitored. Liver imaging and enzymes were used to diagnose NAFLD. It was determined by using the International Diabetes Federation (IDF) and National Cholesterol Education Program Adult Treatment Panel (NCEP ATP III) criteria. Biochemical, hematological, and hepatic enzymes were assessed using standard recommendations. When comparing the mean values of groups, an analysis of variance was utilized (one-way ANOVA). Each character's NAFLD risk was confirmed using a chi-square test. When compared to the control group, individuals with NAFLD had significantly higher levels of body mass index (BMI), waist circumference (WC), and lipid profiles (p ˂ 0.05). In addition, analysis using the NCEP ATP III criteria revealed that 14.56 percent of those with NAFLD also had MetS, indicating that the risk estimate was considerable. On the other hand, additional criteria (IDF) for MetS indicated a greater frequency (29.5%), along with an increased risk for the existence of MetS in NAFLD patients. The variation in triglycerides, also known as TG, and HDL-C showed statistically significant differences among the various grades of NAFLD. Existing co-morbid diseases, such as cardiovascular risk patients (3.89 times higher risk for NAFLD), followed by obese patients (2.85 times higher risk), and Diabetes Mellitus patients (1.46 times higher risk) at a substantial level were shown to be related with a high risk for NAFLD.